Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1998 Sep;125(2):238–240. doi: 10.1038/sj.bjp.0702102

Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease

Janet J Maguire 1,*, Anthony P Davenport 1
PMCID: PMC1565634  PMID: 9786493

Abstract

Overproduction of the potent vasoconstrictor peptide endothelin-1 (ET-1) is implicated in the pathogenesis of coronary artery disease. In endothelium-denuded human coronary arteries the response to big ET-1 was significantly enhanced in atherosclerotic arteries (coronary artery disease, CAD; n=7) with an EC50 value of 96 nM (57–161 nM, 95% C.I.) compared to 274 nM (205–365 nM) in non-diseased arteries (dilated cardiomyopathy, DCM; n=10) (Mann-Whitney U-test, P<0.05). Higher levels of immunoreactive endothelin (ET) could be detected by radioimmunoassay in bathing medium taken from CAD arteries than from DCM arteries (2.8±0.5 nM, n=5 vs 1.1±0.2 nM, n=7) (Student's two-tailed t-test, P<0.05). There were no differences in responses of arteries from either group to ET-1 (EC50 10 nM, CAD vs 14 nM, DCM). The enhanced response of atherosclerotic human coronary arteries to big ET-1 appears to be due to up-regulation of endothelin-converting enzyme (ECE) activity rather than to an augmented response of the arteries to ET-1. This non-endothelial ECE may therefore be an important therapeutic target in coronary artery disease.

Keywords: Atherosclerosis, big endothelin-1, big ET-1, coronary artery disease, ECE, endothelin-1, endothelin-converting enzyme, ET-1, human coronary artery

Full Text

The Full Text of this article is available as a PDF (205.6 KB).


Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES